An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases Abstract #1177

Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.
Aim(s): This study explores whether an abnormal CgB paired with a normal CgA provides any useful clinical information in NET patients.
Materials and methods: A prospective NET database (01/2007-11/2014) was interrogated for paired radioimmunoassay CgA (two assays; normal <6 nmol/L & 60 pmol/L) and CgB (two assays, normal <3 nmol/L, <150 pmol/L) results.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Ron Basuroy

To read results and conclusion, please login ...

Further abstracts you may be interested in

#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#487 Validation of Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: CgA is the most important biochemical marker for evaluation of NETs. Different assays with different accuracy exist.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Lise Brehm Høj
Keywords: neuroendocrine, CgA, assay
#783 A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr. Henning Grønbæk
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1239 Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Logan Mills
Keywords: G3